IRIS UniCatt

Lopetuso, Loris Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.484
EU - Europa 3.149
AS - Asia 1.683
SA - Sud America 336
AF - Africa 36
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 3
Totale 8.702
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.403
SE - Svezia 733
IT - Italia 688
CN - Cina 655
DE - Germania 610
SG - Singapore 554
BR - Brasile 306
FR - Francia 261
IE - Irlanda 210
UA - Ucraina 129
ID - Indonesia 124
GB - Regno Unito 118
FI - Finlandia 92
PL - Polonia 87
IN - India 83
RU - Federazione Russa 77
TR - Turchia 55
CA - Canada 50
KR - Corea 43
HK - Hong Kong 36
BE - Belgio 30
IR - Iran 26
JP - Giappone 22
MX - Messico 22
NL - Olanda 22
VN - Vietnam 18
ES - Italia 16
AR - Argentina 11
CZ - Repubblica Ceca 11
EU - Europa 10
CI - Costa d'Avorio 9
UZ - Uzbekistan 9
ZA - Sudafrica 9
EC - Ecuador 7
EG - Egitto 7
GR - Grecia 6
IQ - Iraq 6
RO - Romania 6
AL - Albania 5
AT - Austria 5
AZ - Azerbaigian 5
IL - Israele 5
LT - Lituania 5
BD - Bangladesh 4
CO - Colombia 4
HU - Ungheria 4
LV - Lettonia 4
NO - Norvegia 4
NP - Nepal 4
RS - Serbia 4
TH - Thailandia 4
TN - Tunisia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
CH - Svizzera 3
CL - Cile 3
EE - Estonia 3
LA - Repubblica Popolare Democratica del Laos 3
PE - Perù 3
PK - Pakistan 3
PT - Portogallo 3
AM - Armenia 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
JM - Giamaica 2
KE - Kenya 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
MA - Marocco 2
MD - Moldavia 2
PH - Filippine 2
PY - Paraguay 2
SA - Arabia Saudita 2
A1 - Anonimo 1
AO - Angola 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
BZ - Belize 1
CY - Cipro 1
DK - Danimarca 1
DZ - Algeria 1
GL - Groenlandia 1
HR - Croazia 1
IS - Islanda 1
JO - Giordania 1
LI - Liechtenstein 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
UG - Uganda 1
Totale 8.702
Salva come PNG Salva come JPEG
Città #
Chandler 817
Singapore 357
Ashburn 292
Dublin 201
Beijing 125
Jakarta 122
New York 117
Cattolica 114
Ann Arbor 93
San Mateo 90
Boston 89
Rome 88
Jacksonville 82
Wilmington 81
Milan 80
Princeton 73
Fairfield 71
Los Angeles 70
Nanjing 68
Warsaw 65
Marseille 62
Woodbridge 52
Moscow 51
The Dalles 50
Dearborn 49
Houston 48
Seattle 48
Hangzhou 45
Helsinki 42
Redwood City 42
Izmir 39
Hefei 36
Seoul 35
North Bergen 33
Frankfurt am Main 31
London 31
Munich 31
Shanghai 29
Lawrence 28
Bremen 27
Brussels 27
Boardman 26
Guangzhou 26
Hong Kong 25
Nuremberg 25
Augusta 24
Pune 23
Shenyang 23
São Paulo 22
Lancaster 21
Nürnberg 21
Redmond 21
Andover 19
Nanchang 19
Tianjin 19
Cambridge 17
Norwalk 17
Jiaxing 16
Kraków 16
Chicago 15
Hebei 15
Toronto 15
Düsseldorf 14
Hyderabad 14
San Francisco 14
Kunming 13
Lauterbourg 13
Mountain View 13
Zhengzhou 13
Tokyo 12
Washington 12
Fremont 11
Kish 11
Lappeenranta 11
Mexico City 11
Changsha 10
Leawood 10
Ottawa 10
Abidjan 9
Belo Horizonte 9
Falkenstein 9
Jinan 9
Portsmouth 9
Trieste 9
Turku 9
Atlanta 8
Falls Church 8
Hanoi 8
Phoenix 8
Bexley 7
Brooklyn 7
Council Bluffs 7
Monza 7
Newark 7
Rio de Janeiro 7
Santa Clara 7
Verona 7
Brno 6
Chennai 6
Paris 6
Totale 4.717
Salva come PNG Salva come JPEG
Nome #
Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. 222
International consensus conference on stool banking for faecal microbiota transplantation in clinical practice 212
Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin 191
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? 164
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease 160
The gut barrier: new acquisitions and therapeutic approaches 153
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 144
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications 143
Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide 143
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders? 138
Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for 'gut barrier protectors' in IBD? 136
13C-octanoic acid breath test to study gastric emptying time 135
Skeletal muscle-gut axis: Emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases 127
The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors 117
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin 116
Actinobacteria: A relevant minority for the maintenance of gut homeostasis 111
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 110
The gastrointestinal microbiome - functional interference between stomach and intestine 104
Gut microbial flora, prebiotics and probiotics in IBD: their current usage and utility 100
Dysbiosis, gut microbiota modulation and intestinal permeability in recurrent cystitis patients and concomitant gastrointestinal pathologies 100
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives 99
Role of yeasts in healthy and impaired gut microbiota: the gut mycome 99
Commensal Clostridia: leading players in the maintenance of gut homeostasis 98
Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility 94
The use of probiotics in different phases of diverticular disease 94
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 94
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives 93
Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome? 91
Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders 90
Bacillus clausii and gut homeostasis: state of the art and future perspectives 89
Gut microbiota profiling and gut-brain crosstalk in children affected by pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections 86
Microbes and Alzheimer' disease: Lessons from H. Pylori and GUT microbiota 86
Specific 13C functional pathways as diagnostic targets in gastroenterology breath-tests: tricks for a correct interpretation 85
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 83
Dietary Magnesium Alleviates Experimental Murine Colitis Through Upregulation of the Transient Receptor Potential Melastatin 6 Channel 81
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 80
Gut microbiota and inflammatory bowel disease: an update 79
Development and validation of predictive assessment of complicated diverticulitis score 79
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 78
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 77
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 76
Secretome modulation of Caco-2 cell line induced by a multi-strain probiotic 76
Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats 75
Can we predict the efficacy of anti-TNF-α agents? 74
Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 74
Microparticles produced by activated platelets carry a potent and functionally active angiogenic signal in subjects with crohn’s disease 72
Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals 72
Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care 69
Considering gut microbiota disturbance in the management of Helicobacter pylori infection 69
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study 69
Intestinal permeability in physiological and pathological conditions: major determinants and assessment modalities 69
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease 68
Bacillus clausii for the treatment of acute diarrhea in children: A systematic review and meta-analysis of randomized controlled trials 68
Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma 68
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 68
Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey 67
Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study 65
Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection—single versus multiple infusions 63
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 63
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 61
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 61
Gut Virome and Inflammatory Bowel Disease 60
Coeliac disease under a microscope: Histological diagnostic features and confounding factors 60
SECRETOME MODULATION OF CACO2 CELL LINE INDUCED BY A MULTI-STRAIN PROBIOTIC 60
How to face the advent of sars-cov-2 vaccination in ibd patients: Another task for gastroenterologists 60
Esophageal microbiome signature in patients with Barrett’s esophagus and esophageal adenocarcinoma 60
Radiomics could predict surgery at 10 years in Crohn's disease 59
Relationship between oral microbiota and periodontal disease: a systematic review 59
Infliximab does not increase colonic cancer risk associated to murine chronic colitis 59
[Ulcerative colitis] 58
Anti-TNF-α-induced psoriasiform lesions in IBD: An abnormal immune activation or a 'patchy cutaneous' immune suppression? 58
A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn’s disease patients 56
Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: A multidisciplinary management experience 55
Orphan patients with inflammatory bowel disease - when we treat beyond evidence 55
Impact of the Trophic Effects of the Secretome from a Multistrain Probiotic Preparation on the Intestinal Epithelia 55
Gut Microbiota Signatures Are Associated With Psychopathological Profiles in Patients With Ulcerative Colitis: Results From an Italian Tertiary IBD Center 54
Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation 54
Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: An update 53
The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease 52
Assessment of Crohn's Disease Activity: Magnetic Resonance Enterography in Comparison with Clinical and Endoscopic Evaluations 52
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 52
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 51
Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: A case report and review of the literature 51
The “dica” endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists 50
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 50
Role of microbiota and innate immunity in recurrent Clostridium difficile infection 49
Bacteriocins and Bacteriophages: Therapeutic Weapons for Gastrointestinal Diseases? 49
The thrilling journey of sars-cov-2 into the intestine: From pathogenesis to future clinical implications 48
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 48
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 47
Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study 47
Bariatric procedures and microbiota: patient selection and outcome prediction 46
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 45
Anti-tumor necrosis factor α therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis 45
Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila 45
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment 45
The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center 45
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 44
Gut microbiota during dietary restrictions: New insights in non-communicable diseases 44
Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease 42
Totale 8.050
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.504
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.504
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202037 0 0 0 0 0 0 0 0 0 0 0 37
2020/2021667 73 81 14 52 77 54 50 14 59 37 128 28
2021/2022949 93 35 23 66 70 25 12 135 48 94 180 168
2022/20232.211 311 305 165 348 136 248 105 178 240 37 77 61
2023/20241.248 77 315 55 76 42 175 82 52 56 47 128 143
2024/20252.103 59 74 207 62 180 85 121 110 335 297 527 46
Totale 8.891